L
4.24
0.32 (8.16%)
| Previous Close | 3.92 |
| Open | 3.88 |
| Volume | 423,344 |
| Avg. Volume (3M) | 1,041,977 |
| Market Cap | 140,733,648 |
| Price / Book | 1.60 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Diluted EPS (TTM) | -3.31 |
| Total Debt/Equity (MRQ) | 10.67% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | -88.00 M |
| Levered Free Cash Flow (TTM) | -50.43 M |
| Return on Assets (TTM) | -42.89% |
| Return on Equity (TTM) | -80.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Lexeo Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 121.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| D1 Capital Partners L.P. | 31 Mar 2025 | 978,652 |
| Avidity Partners Management Lp | 31 Mar 2025 | 645,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Chardan Capital, 371.70%) | Buy |
| 20.00 (RBC Capital, 371.70%) | Buy | |
| Median | 18.00 (324.53%) | |
| Low | 10.00 (JP Morgan, 135.85%) | Buy |
| Average | 16.60 (291.51%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 3.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 30 May 2025 | 10.00 (135.85%) | Buy | 2.72 |
| HC Wainwright & Co. | 16 May 2025 | 15.00 (253.77%) | Buy | 3.24 |
| 08 Apr 2025 | 23.00 (442.45%) | Buy | 1.82 | |
| Chardan Capital | 13 May 2025 | 20.00 (371.70%) | Buy | 2.83 |
| 08 Apr 2025 | 22.00 (418.87%) | Buy | 1.82 | |
| RBC Capital | 25 Mar 2025 | 20.00 (371.70%) | Buy | 4.44 |
| Leerink Partners | 24 Mar 2025 | 18.00 (324.53%) | Buy | 4.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 May 2025 | Announcement | Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights |
| 01 May 2025 | Announcement | Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting |
| 07 Apr 2025 | Announcement | Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study |
| 24 Mar 2025 | Announcement | Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |